

Mark Bolland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7403356/publications.pdf>

Version: 2024-02-01

271
papers

13,507
citations

36691

53
h-index

27587

110
g-index

282
all docs

282
docs citations

282
times ranked

12899
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted. <i>Accountability in Research</i> , 2024, 31, 14-37.	1.6	5
2	Citation of retracted publications: A challenging problem. <i>Accountability in Research</i> , 2022, 29, 18-25.	1.6	31
3	Decreased thyroid FNA but increased ultrasound: Is the trade-off worthwhile?. <i>Clinical Endocrinology</i> , 2022, 96, 922-922.	1.2	0
4	Timeliness and content of retraction notices for publications by a single research group. <i>Accountability in Research</i> , 2022, 29, 347-378.	1.6	13
5	Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 196-205.	1.3	14
6	Diversity of invited speakers at endocrinology conferences. <i>Clinical Endocrinology</i> , 2022, 96, 907-913.	1.2	3
7	Nonoperative Management of Mild Primary Hyperparathyroidism: A Reasonable, Evidence-Based Option. <i>Annals of Internal Medicine</i> , 2022, , .	2.0	0
8	Correcting the scientific record – A broken system?. <i>Accountability in Research</i> , 2021, 28, 265-279.	1.6	10
9	Population vitamin D supplementation in UK adults: too much of nothing?. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 7-12.	0.3	2
10	Participant withdrawals were unusually distributed in randomized trials with integrity concerns: a statistical investigation. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 22-29.	2.4	7
11	Clinical trial registry documents and publication integrity. <i>Accountability in Research</i> , 2021, 28, 149-161.	1.6	6
12	Vitamin D supplementation and testing in the UK: costly but ineffective?. <i>BMJ, The</i> , 2021, 372, n484.	3.0	8
13	Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing. <i>Clinical Endocrinology</i> , 2021, 95, 74-83.	1.2	4
14	Identical summary statistics were uncommon in randomized trials and cohort studies. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 180-188.	2.4	5
15	Participant injury in clinical trials conducted in New Zealand for the benefit of manufacturers: an unfair system?. <i>New Zealand Medical Journal</i> , 2021, 134, 124-131.	0.5	0
16	Vitamin D deficiency, supplementation and testing: have we got it right in New Zealand?. <i>New Zealand Medical Journal</i> , 2021, 134, 86-95.	0.5	0
17	Assessing and Raising Concerns About Duplicate Publication, Authorship Transgressions and Data Errors in a Body of Preclinical Research. <i>Science and Engineering Ethics</i> , 2020, 26, 2069-2096.	1.7	14
18	Check for publication integrity before misconduct. <i>Nature</i> , 2020, 577, 167-169.	13.7	64

#	ARTICLE	IF	CITATIONS
19	Empirically generated reference proportions for baseline p values from rounded summary statistics. <i>Anaesthesia</i> , 2020, 75, 1685-1687.	1.8	16
20	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1040-1047.	3.1	6
21	Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, <i>Am J Med.</i> 2004;117:549-555. <i>American Journal of Medicine</i> , 2020, 133, e311-e314.	0.6	4
22	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1641-e1647.	1.8	28
23	Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. <i>Nutrients</i> , 2020, 12, 1011.	1.7	43
24	Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 61-66.	3.1	8
25	Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 3-11.	3.1	14
26	Thyroid ultrasound and nodule malignancy risk: a "real world" assessment of ultrasound reporting and agreement of ultrasound-based malignancy risk estimates with cytology and histology findings. <i>New Zealand Medical Journal</i> , 2020, 133, 20-27.	0.5	1
27	25-Hydroxyvitamin D "Should labs be measuring it?". <i>Annals of Clinical Biochemistry</i> , 2019, 56, 188-189.	0.8	7
28	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. <i>Calcified Tissue International</i> , 2019, 105, 423-429.	1.5	3
29	Correcting Meta-analyses and Reviews Affected by Retracted Research. <i>JAMA Internal Medicine</i> , 2019, 179, 1005.	2.6	1
30	Controversies in medicine: the role of calcium and vitamin D supplements in adults. <i>Medical Journal of Australia</i> , 2019, 211, 468-473.	0.8	43
31	Vitamin D supplementation and musculoskeletal health "Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 88-89.	5.5	3
32	Baseline P value distributions in randomized trials were uniform for continuous but not categorical variables. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 67-76.	2.4	16
33	Rounding, but not randomization method, non-normality, or correlation, affected baseline P-value distributions in randomized trials. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 50-62.	2.4	18
34	Publication rates after the first retraction for biomedical researchers with multiple retracted publications. <i>Accountability in Research</i> , 2019, 26, 277-287.	1.6	11
35	Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2019, 286, 221-229.	2.7	21
36	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1248-1253.	3.1	13

#	ARTICLE	IF	CITATIONS
37	Quality of reports of investigations of research integrity by academic institutions. <i>Research Integrity and Peer Review</i> , 2019, 4, 3.	2.2	23
38	An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. <i>BMJ Open</i> , 2019, 9, e031909.	0.8	36
39	Evaluating ethics oversight during assessment of research integrity. <i>Research Integrity and Peer Review</i> , 2019, 4, 22.	2.2	1
40	Calcium supplementation in osteoporosis: useful or harmful?. <i>European Journal of Endocrinology</i> , 2018, 178, D13-D25.	1.9	55
41	Concerns About the Integrity of Sato et al. <i>Am J Med</i> . 2005;118:1250-1255. <i>American Journal of Medicine</i> , 2018, 131, e107-e108.	0.6	4
42	Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. <i>Neurology</i> , 2018, 90, 627-628.	1.5	1
43	Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals. <i>Trials</i> , 2018, 19, 592.	0.7	3
44	Enough data to draw conclusions about vitamin D and bone health. <i>BMJ: British Medical Journal</i> , 2018, 363, k4755.	2.4	0
45	A randomised investigation of journal responses to academic and journalist enquiry about possible scientific misconduct. <i>BMC Research Notes</i> , 2018, 11, 521.	0.6	7
46	Fracture Prevention with Zoledronate in Older Women with Osteopenia. <i>New England Journal of Medicine</i> , 2018, 379, 2407-2416.	13.9	280
47	Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 847-858.	5.5	303
48	Assessment of research waste part 2: wrong study populations- an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation. <i>BMC Medical Research Methodology</i> , 2018, 18, 101.	1.4	27
49	Assessment of research waste part 1: an exemplar from examining study design, surrogate and clinical endpoints in studies of calcium intake and vitamin D supplementation. <i>BMC Medical Research Methodology</i> , 2018, 18, 103.	1.4	9
50	A closer look at SCOOP: screening for fracture prevention. <i>Lancet</i> , 2018, 392, 551-552.	6.3	1
51	Revised Meta-analysis of Vitamin K and Fractures. <i>JAMA Internal Medicine</i> , 2018, 178, 1135.	2.6	2
52	Author response: Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. <i>Neurology</i> , 2018, 90, 578-578.	1.5	0
53	Inaccurate retraction notice for meta-analysis by Iwamoto et al. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 263-263.	1.0	2
54	Do vitamin D supplements help prevent respiratory tract infections?. <i>BMJ: British Medical Journal</i> , 2017, 356, j456.	2.4	13

#	ARTICLE	IF	CITATIONS
55	Neglect or good practice? Authorsâ€™ reply to letters by Rhein and Degner. BMJ: British Medical Journal, 2017, 356, j716.	2.4	0
56	Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open, 2017, 7, e013703.	0.8	13
57	Cessation of strontium ranelate supply. BMJ: British Medical Journal, 2017, 357, j2580.	2.4	3
58	Maintaining Order in Osteoporosis Treatments. Journal of Bone and Mineral Research, 2017, 32, 1147-1147.	3.1	1
59	Conflicts of interest and expertise of independent commenters in news stories about medical research. Cmaj, 2017, 189, E553-E559.	0.9	11
60	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. Cmaj, 2017, 189, E1130-E1136.	0.9	34
61	Are more trials of calcium supplements really needed?. Osteoporosis International, 2017, 28, 2729-2730.	1.3	1
62	Calcium Intake and Cardiovascular Disease Risk. Annals of Internal Medicine, 2017, 166, 684.	2.0	7
63	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. Osteoporosis International, 2017, 28, 733-734.	1.3	7
64	Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ: British Medical Journal, 2017, 359, j4849.	2.4	320
65	Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study. BMJ Open, 2017, 7, e017019.	0.8	19
66	Calcium and Cardiovascular Disease. Endocrinology and Metabolism, 2017, 32, 339.	1.3	75
67	Review: Dietary or supplemental calcium increase BMD by 1.8% in persons >50 years of age. Annals of Internal Medicine, 2016, 164, JC5.	2.0	2
68	Management recommendations for osteoporosis in clinical guidelines. Clinical Endocrinology, 2016, 84, 687-692.	1.2	15
69	Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. BMJ, The, 2016, 354, i5109.	3.0	21
70	Should adults take vitamin D supplements to prevent disease?. BMJ, The, 2016, 355, i6201.	3.0	28
71	Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas. Infection, 2016, 44, 607-615.	2.3	23
72	Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology, 2016, 87, 2391-2402.	1.5	92

#	ARTICLE	IF	CITATIONS
73	We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations. <i>BMJ, The</i> , 2016, 355, i5383.	3.0	19
74	News coverage of clinical research. <i>BMJ, The</i> , 2016, 352, i1177.	3.0	2
75	Inaccurate dissemination of the MAVIDOS trial results. <i>Lancet Diabetes and Endocrinology, the</i> , 2016, 4, 481.	5.5	2
76	Errors in NOF meta-analyses of calcium and vitamin D supplements. <i>Osteoporosis International</i> , 2016, 27, 2637-2639.	1.3	5
77	Vitamin D supplements do not prevent falls. <i>BMJ, The</i> , 2016, 353, i3005.	3.0	3
78	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. <i>Lancet Diabetes and Endocrinology, the</i> , 2016, 4, 569-576.	5.5	151
79	Qualitative research, observational research, and The BMJ. <i>BMJ, The</i> , 2016, 352, i1483.	3.0	2
80	Circulating calcium concentrations, vascular disease and mortality: a systematic review. <i>Journal of Internal Medicine</i> , 2016, 279, 524-540.	2.7	97
81	Outcomes of bone density measurements in coeliac disease. <i>New Zealand Medical Journal</i> , 2016, 129, 40-4.	0.5	3
82	Mendelian Randomization Analysis to Examine for a Causal Effect of Urate on Bone Mineral Density. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 985-991.	3.1	50
83	Calcium supplements: benefits and risks. <i>Journal of Internal Medicine</i> , 2015, 278, 354-368.	2.7	101
84	Screening for Vitamin D Deficiency. <i>Annals of Internal Medicine</i> , 2015, 162, 736.	2.0	0
85	Different outcomes of meta-analyses and data inconsistency: response to comments by Pfeifer. <i>Archives of Osteoporosis</i> , 2015, 10, 43.	1.0	3
86	Evolution of Paget's disease of bone in adults inheriting <i>SCN1A</i> mutations. <i>Clinical Endocrinology</i> , 2015, 83, 315-319.	1.2	26
87	Reporting of Limitations of Observational Research. <i>JAMA Internal Medicine</i> , 2015, 175, 1571.	2.6	39
88	Web of industry, advocacy, and academia in the management of osteoporosis. <i>BMJ, The</i> , 2015, 351, h3170.	3.0	27
89	The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. <i>Diabetologia</i> , 2015, 58, 2238-2246.	2.9	104
90	Bone density is normal and does not change over 2 years in sarcoidosis. <i>Osteoporosis International</i> , 2015, 26, 611-616.	1.3	13

#	ARTICLE	IF	CITATIONS
91	Calcium intake and bone mineral density: systematic review and meta-analysis. <i>BMJ, The</i> , 2015, 351, h4183.	3.0	272
92	Calcium intake and risk of fracture: systematic review. <i>BMJ, The</i> , 2015, 351, h4580.	3.0	241
93	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. <i>Climacteric</i> , 2015, 18, 22-31.	1.1	44
94	Inconsistent data in text and tables. <i>Osteoporosis International</i> , 2015, 26, 2713-2713.	1.3	4
95	Vitamin D Supplements and the Risk of Falls. <i>JAMA Internal Medicine</i> , 2015, 175, 1723.	2.6	4
96	Cardiovascular Complications of Calcium Supplements. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 494-501.	1.2	30
97	Calcium Supplements Increase Risk of Myocardial Infarction. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 389-390.	3.1	14
98	Skeletal health in adults with HIV infection. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 63-74.	5.5	36
99	Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2015, 26, 499-503.	1.3	37
100	Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. <i>Osteoporosis International</i> , 2015, 26, 173-178.	1.3	1
101	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. <i>PLoS ONE</i> , 2015, 10, e0139975.	1.1	10
102	Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0145294.	1.1	13
103	Are trials of vitamin D with mortality as an endpoint really needed?. <i>BMJ, The</i> , 2014, 349, g4452-g4452.	3.0	1
104	Press Releases Issued by Supplements Industry Organisations and Non-Industry Organisations in Response to Publication of Clinical Research Findings: A Case-Control Study. <i>PLoS ONE</i> , 2014, 9, e101533.	1.1	6
105	Authors' reply to MacDonald and Etminan. <i>BMJ, The</i> , 2014, 349, g5523-g5523.	3.0	0
106	Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer. <i>Annals of Internal Medicine</i> , 2014, 160, 655.	2.0	3
107	Calcium supplements associated with increased risk of cardiovascular death in men but not women. <i>Evidence-based Nursing</i> , 2014, 17, 90-90.	0.1	2
108	Response to letter to editor. <i>Osteoporosis International</i> , 2014, 25, 2501-2501.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4265-4272.	1.8	53
110	A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. <i>BMJ Open</i> , 2014, 4, e005787.	0.8	30
111	Calcium Supplements and Fracture Prevention. <i>New England Journal of Medicine</i> , 2014, 370, 386-388.	13.9	13
112	Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 166-172.	3.1	21
113	Benefits of Calcium Supplements Are Too Small for Clinical Equipoise to Exist. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1914-1915.	3.1	1
114	Clinical Trial Evidence and Use of Fish Oil Supplements. <i>JAMA Internal Medicine</i> , 2014, 174, 460.	2.6	49
115	Vitamin D supplements and bone mineral density – Authors' reply. <i>Lancet</i> , The, 2014, 383, 1293-1294.	6.3	1
116	Calcium risk – benefit updated – New WHI analyses. <i>Maturitas</i> , 2014, 77, 1-3.	1.0	31
117	The Auckland calcium study: 5-year post-trial follow-up. <i>Osteoporosis International</i> , 2014, 25, 297-304.	1.3	25
118	Vitamin D supplementation and falls: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 573-580.	5.5	149
119	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 307-320.	5.5	371
120	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. <i>Lancet</i> , The, 2014, 383, 146-155.	6.3	497
121	Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 746-755.	2.2	229
122	Vitamin D and falls – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 541.	5.5	0
123	Unhelpful information about adverse drug reactions. <i>BMJ</i> , The, 2014, 349, g5019-g5019.	3.0	52
124	Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. <i>Osteoporosis International</i> , 2014, 25, 2347-2357.	1.3	43
125	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2014, 170, 255-262.	1.9	37
126	Republished: Paget's disease of bone: clinical review and update. <i>Postgraduate Medical Journal</i> , 2014, 90, 328-331.	0.9	1

#	ARTICLE	IF	CITATIONS
127	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 364-365.	5.5	9
128	Vitamin D supplements do not reduce mortality risk. <i>BMJ</i> , 2014, 348, g2860-g2860.	3.0	4
129	Results of Observational Studies: Analysis of Findings from the Nurses' Health Study. <i>PLoS ONE</i> , 2014, 9, e110403.	1.1	21
130	A Case Study of Discordant Overlapping Meta-Analyses: Vitamin D Supplements and Fracture. <i>PLoS ONE</i> , 2014, 9, e115934.	1.1	47
131	Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 94-101.	0.5	3
132	Diagnostic category agreement and malignancy rates in clinician-categorised, non-standardised thyroid cytology reports. <i>New Zealand Medical Journal</i> , 2014, 127, 49-55.	0.5	0
133	Calcium supplements and cardiovascular risk in the Women's Health Initiative. <i>Osteoporosis International</i> , 2013, 24, 2371-2372.	1.3	4
134	Testosterone Levels Following Decreases in Serum Osteocalcin. <i>Calcified Tissue International</i> , 2013, 93, 133-136.	1.5	15
135	A pooled analysis of Vitamin D dose requirements for fracture prevention. <i>IBMS BoneKEy</i> , 2013, 10, .	0.1	3
136	Antiretroviral Preexposure Prophylaxis for HIV Prevention. <i>New England Journal of Medicine</i> , 2013, 368, 82-84.	13.9	31
137	The effect of treatments for osteoporosis on mortality. <i>Osteoporosis International</i> , 2013, 24, 1-6.	1.3	45
138	Comment on Kanis et al.: Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2013, 24, 389-390.	1.3	9
139	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. <i>Osteoporosis International</i> , 2013, 24, 349-354.	1.3	20
140	Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2013, 110, 1384-1393.	1.2	81
141	Calcium supplements and cardiovascular risk: 5 years on. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 199-210.	1.0	55
142	Strontium and cardiovascular events. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e22-e22.	0.5	3
143	Paget's disease of bone: clinical review and update. <i>Journal of Clinical Pathology</i> , 2013, 66, 924-927.	1.0	47
144	Randomised controlled trial of vitamin D supplementation in sarcoidosis. <i>BMJ Open</i> , 2013, 3, e003562.	0.8	33

#	ARTICLE	IF	CITATIONS
145	Discrepancies in predicted fracture risk in elderly people. <i>BMJ, The</i> , 2013, 346, e8669-e8669.	3.0	28
146	Subgroup analysis for the risk of cardiovascular disease with calcium supplements. <i>BoneKEY Reports</i> , 2013, 2, 293.	2.7	15
147	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2301-2307.	1.8	20
148	Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. <i>BMJ Open</i> , 2013, 3, e002334.	0.8	16
149	What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. <i>BMJ, The</i> , 2013, 346, f3413-f3413.	3.0	1
150	Convicted at a Show Trial. <i>British Journalism Review</i> , 2013, 24, 19-23.	0.0	0
151	Observational studies—just telling us what we want to hear or telling us where we need to look?. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 980-983.	3.1	1
152	Nonsustained hypercalcaemia and primary hyperparathyroidism in the <sc>PEARS</sc> cohort. <i>Clinical Endocrinology</i> , 2013, 79, 899-899.	1.2	0
153	An inappropriate response?. <i>BMJ, The</i> , 2013, 346, f942-f942.	3.0	3
154	Authors' reply to McCloskey and colleagues. <i>BMJ, The</i> , 2013, 346, f1440-f1440.	3.0	0
155	Calcium and cardiovascular risks. <i>Australian Prescriber</i> , 2013, 36, 148-149.	0.5	0
156	Reply to RT Chlebowski et al. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 259.	2.2	1
157	Vitamin D Dose Requirements for Fracture Prevention. <i>New England Journal of Medicine</i> , 2012, 367, 1367-1370.	13.9	6
158	Calcium supplements: bad for the heart?. <i>Heart</i> , 2012, 98, 895-896.	1.2	36
159	Calcium supplements and cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2012, 9, 497-498.	6.1	7
160	Comment: Assessing the Potential Adverse Consequences of Supplemental Calcium on Cardiovascular Outcomes: Should We Change Our Approach to Bone Health?. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1267-1268.	0.9	0
161	Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2012, 166, 1087-1091.	1.9	43
162	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1922-1928.	1.8	50

#	ARTICLE	IF	CITATIONS
163	Severe Vitamin D Deficiency: A Prerequisite for Chronic Obstructive Pulmonary Disease Responsiveness to Vitamin D Supplementation?. <i>Annals of Internal Medicine</i> , 2012, 156, 904.	2.0	0
164	Low-Dose Zoledronate in Osteopenic Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 349-350.	0.2	0
165	Vitamin D testing. <i>Lancet, The</i> , 2012, 379, 1699.	6.3	3
166	Vitamin D testing. <i>Lancet, The</i> , 2012, 379, 1699-1700.	6.3	2
167	Vitamin D and tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3528-E3528.	3.3	2
168	Calcium Supplements and Risk of Myocardial Infarction: An Hypothesis Twice Tested. <i>American Journal of Medicine</i> , 2012, 125, e15.	0.6	10
169	Effect of osteoporosis treatment on mortality. <i>Bone</i> , 2012, 50, S27.	1.4	0
170	Five years of anti-resorptive effects after 1 or 2 doses of zoledronate â€” Data from 2 randomized controlled trials. <i>Bone</i> , 2012, 50, S46-S47.	1.4	1
171	Five years of anti-resorptive activity after a single dose of zoledronate â€” Results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012, 50, 1389-1393.	1.4	83
172	Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292.	1.8	43
173	Role of vitamin D deficiency in cardiovascular disease. <i>Heart</i> , 2012, 98, 609-614.	1.2	38
174	Vitamin D and health in adults in Australia and New Zealand: a position statement. <i>Medical Journal of Australia</i> , 2012, 197, 553-553.	0.8	3
175	Misclassification does not explain increased cardiovascular risks of calcium supplements. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 959-959.	3.1	9
176	Stable bone mineral density over 6â€”years in HIVâ€”infected men treated with highly active antiretroviral therapy (HAART). <i>Clinical Endocrinology</i> , 2012, 76, 643-648.	1.2	24
177	Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?. <i>New Zealand Medical Journal</i> , 2012, 125, 83-91.	0.5	3
178	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Womenâ€™s Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1144-1149.	2.2	243
179	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d2040-d2040.	2.4	740
180	Calcium supplementation: Balancing the cardiovascular risks. <i>Maturitas</i> , 2011, 69, 289-295.	1.0	34

#	ARTICLE	IF	CITATIONS
181	Authors' response to editorial. BMJ: British Medical Journal, 2011, 342, d3520-d3520.	2.4	5
182	Decreased bone density in men on methadone maintenance therapy. Addiction, 2011, 106, 349-354.	1.7	53
183	Management of primary hyperparathyroidism. Clinical Endocrinology, 2011, 75, 722-722.	1.2	0
184	Mortality and morbidity in Cushing's syndrome in New Zealand. Clinical Endocrinology, 2011, 75, 436-442.	1.2	149
185	Calcium supplements and cardiovascular disease - picking the spin. International Journal of Clinical Practice, 2011, 65, 226-227.	0.8	3
186	Cardiovascular effects of calcium supplementation. Osteoporosis International, 2011, 22, 1649-1658.	1.3	93
187	Re: The calcium score: what would Austin Bradford Hill have thought?. Osteoporosis International, 2011, 22, 3079-3080.	1.3	8
188	Familial Paget Disease and SQSTM1 Mutations in New Zealand. Calcified Tissue International, 2011, 89, 258-264.	1.5	13
189	Evaluation of the FRAX and Garvan fracture risk calculators in older women. Journal of Bone and Mineral Research, 2011, 26, 420-427.	3.1	158
190	Calcium supplements and cardiovascular risk. Journal of Bone and Mineral Research, 2011, 26, 899-899.	3.1	8
191	Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2721-2731.	1.8	68
192	Vitamin D Supplementation and Fracture Risk—Reply. Archives of Internal Medicine, 2011, 171, 265.	4.3	0
193	Fracture-risk calculators: Has their time come?. Cmaj, 2011, 183, 171-172.	0.9	3
194	Prevalent dietary supplement use in older New Zealand men. New Zealand Medical Journal, 2011, 124, 55-62.	0.5	4
195	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. Obstetrical and Gynecological Survey, 2010, 65, 514-515.	0.2	2
196	Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. Journal of Bone and Mineral Research, 2010, 25, 505-512.	3.1	74
197	Response to publication of PRISM trial. Journal of Bone and Mineral Research, 2010, 25, 1463-1464.	3.1	9
198	Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. Journal of Bone and Mineral Research, 2010, 25, 2251-2255.	3.1	57

#	ARTICLE	IF	CITATIONS
199	Relationships between vascular calcification, calcium metabolism, bone density, and fractures. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2777-2785.	3.1	83
200	Investigating harms in clinical trials - no easy task. <i>International Journal of Clinical Practice</i> , 2010, 64, 1719-1722.	0.8	1
201	Does calcium supplementation increase cardiovascular risk?. <i>Clinical Endocrinology</i> , 2010, 73, 689-695.	1.2	73
202	Morbidity and mortality in mild primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2010, 73, 688-688.	1.2	1
203	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1253.	3.8	3
204	Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1653-1662.	1.8	85
205	Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 131-139.	2.2	91
206	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1253.	3.8	10
207	Vitamin D Supplementation. <i>Archives of Internal Medicine</i> , 2010, 170, 572.	4.3	2
208	Vitamin D insufficiency and health outcomes over 5 y in older women. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 82-89.	2.2	119
209	Disparate Outcomes from Applying U.K. and U.S. Osteoporosis Treatment Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1856-1860.	1.8	36
210	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1174-1181.	1.8	285
211	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. <i>BMJ: British Medical Journal</i> , 2010, 341, c3691-c3691.	2.4	931
212	Benefits of Vitamin D?. <i>American Journal of Medicine</i> , 2010, 123, e17.	0.6	0
213	"Cherry picking" did not occur in studied example. <i>BMJ: British Medical Journal</i> , 2010, 341, c5009-c5009.	2.4	3
214	Reporting of absolute risk. <i>BMJ: British Medical Journal</i> , 2010, 341, c6331-c6331.	2.4	1
215	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. <i>BMJ: British Medical Journal</i> , 2010, 341, c6923-c6923.	2.4	1
216	Vitamin D Deficiency and Its Health Consequences in New Zealand. , 2010, , 589-601.		0

#	ARTICLE	IF	CITATIONS
217	Trials of Vertebroplasty for Vertebral Fractures. <i>New England Journal of Medicine</i> , 2009, 361, 2097-2100.	13.9	47
218	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 538-544.	1.8	100
219	Effect of calcium supplementation on hip fractures: reply to correspondence. <i>Osteoporosis International</i> , 2009, 20, 835-836.	1.3	4
220	Calcium supplementation for older men and women?. <i>Osteoporosis International</i> , 2009, 20, 2147-2148.	1.3	2
221	Is calcium supplementation a risk factor for cardiovascular diseases in older women?. <i>Nutrition Reviews</i> , 2009, 67, 424-424.	2.6	2
222	Effective osteoporosis treatments reduce mortality: A meta-analysis. <i>Bone</i> , 2009, 44, S38.	1.4	0
223	Do Calcium Supplements Lead to an Increase in Coronary Calcification?. <i>Heart Lung and Circulation</i> , 2009, 18, S28-S29.	0.2	0
224	Role of ultrasound in the assessment of nodular thyroid disease. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2009, 53, 177-187.	0.9	55
225	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 462-463.	0.2	1
226	Time for a moratorium on vitamin D meta-analyses?. <i>BMJ: British Medical Journal</i> , 2009, 339, b4394-b4394.	2.4	15
227	Trials of vertebroplasty for vertebral fractures. <i>New England Journal of Medicine</i> , 2009, 361, 2098-9; author reply 2099-100.	13.9	15
228	Effect of calcium supplementation on hip fractures. <i>Osteoporosis International</i> , 2008, 19, 1119-1123.	1.3	111
229	Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2008, 7, 3.	1.7	12
230	Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1304-1308.	3.1	41
231	Paget disease of bone. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 246-253.	3.1	52
232	Bilateral Transient Osteoporosis of the Hip in a Young Man. <i>Journal of Clinical Densitometry</i> , 2008, 11, 339-341.	0.5	12
233	Calcium supplementation and vascular disease. <i>Climacteric</i> , 2008, 11, 280-286.	1.1	22
234	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2008, 336, 262-266.	2.4	585

#	ARTICLE	IF	CITATIONS
235	The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. <i>Rheumatology</i> , 2008, 48, 195-197.	0.9	26
236	Randomized Controlled Trial of Calcium Supplementation in Healthy, Nonosteoporotic, Older Men. <i>Archives of Internal Medicine</i> , 2008, 168, 2276.	4.3	122
237	A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 89-95.	1.9	409
238	Artifact in the control group undermines the conclusions of a vitamin D and cancer study. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-792.	2.2	14
239	Does degree of baldness influence vitamin D status?. <i>Medical Journal of Australia</i> , 2008, 189, 674-675.	0.8	19
240	Calcium supplementation and cancer incidence. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-793.	2.2	12
241	Calcium supplementation does not increase mortality. <i>Medical Journal of Australia</i> , 2008, 189, 55-56.	0.8	1
242	Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. <i>New Zealand Medical Journal</i> , 2008, 121, 18-29.	0.5	4
243	The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. <i>New Zealand Medical Journal</i> , 2008, 121, 63-74.	0.5	44
244	Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4522-4528.	1.8	118
245	The Peroxisome Proliferator-Activated Receptor- β Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1305-1310.	1.8	399
246	Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1283-1288.	1.8	119
247	Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. <i>Clinical Chemistry</i> , 2007, 53, 1109-1114.	1.5	22
248	The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 959-964.	2.2	173
249	Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. <i>Bone</i> , 2007, 41, 318-320.	1.4	332
250	Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. <i>Clinical Endocrinology</i> , 2007, 67, 259-264.	1.2	73
251	Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. <i>Clinical Endocrinology</i> , 2007, 67, 270-275.	1.2	49
252	Delayed Development of Paget's Disease in Offspring Inheriting SQSTM1 Mutations. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 411-415.	3.1	73

#	ARTICLE	IF	CITATIONS
253	The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. <i>Osteoporosis International</i> , 2007, 18, 479-486.	1.3	115
254	Vitamin D sufficiency: reply to letter by Heaney. <i>Osteoporosis International</i> , 2007, 18, 835-836.	1.3	1
255	The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. <i>New Zealand Medical Journal</i> , 2007, 120, U2804.	0.5	3
256	Randomized Controlled Trial of Calcium in Healthy Older Women. <i>American Journal of Medicine</i> , 2006, 119, 777-785.	0.6	249
257	Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. <i>Bone</i> , 2006, 38, 317-321.	1.4	126
258	Osteonecrosis of the jaw and bisphosphonates. <i>BMJ: British Medical Journal</i> , 2006, 333, 1122.3-1123.	2.4	1
259	Gastrointestinal stromal tumour in succinate dehydrogenase subunit B mutation-associated familial pheochromocytoma/paraganglioma. <i>ANZ Journal of Surgery</i> , 2006, 76, 763-764.	0.3	17
260	Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. <i>Clinical Endocrinology</i> , 2006, 65, 191-197.	1.2	45
261	Determinants of vitamin D status in older men living in a subtropical climate. <i>Osteoporosis International</i> , 2006, 17, 1742-1748.	1.3	70
262	A case of low cortisol-binding globulin: use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis tests. <i>Annals of Clinical Biochemistry</i> , 2006, 43, 237-239.	0.8	19
263	Osteonecrosis of the jaw and bisphosphonates—putting the risk in perspective. <i>New Zealand Medical Journal</i> , 2006, 119, U2339.	0.5	5
264	Determinants of vitamin D status in older women living in a subtropical climate. <i>Osteoporosis International</i> , 2005, 16, 1641-1648.	1.3	121
265	Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1525-1530.	1.8	183
266	Effects of a β -Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5212-5216.	1.8	97
267	Evaluation and Treatment of Primary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2699-2700.	3.8	1
268	Heterophile antibodies may cause falsely lowered serum cortisol values. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 643-645.	1.8	27
269	Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole. <i>Annals of Pharmacotherapy</i> , 2004, 38, 46-49.	0.9	90
270	Antioxidant supplements for preventing gastrointestinal cancers. , 2004, , CD004183.		31

#	ARTICLE	IF	CITATIONS
271	Bilateral Femoral Head Osteonecrosis After Septic Shock and Multiorgan Failure. Journal of Bone and Mineral Research, 2003, 19, 517-520.	3.1	15